<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03778112</url>
  </required_header>
  <id_info>
    <org_study_id>mpMRI SBRT Prostate</org_study_id>
    <secondary_id>15060207</secondary_id>
    <nct_id>NCT03778112</nct_id>
  </id_info>
  <brief_title>MRI Guided SBRT for Localized Prostate Cancer</brief_title>
  <official_title>Prospective Evaluation of Multi-Parametric MRI Guided Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study utilizes advanced imaging techniques (mpMRI prostate scan) to select and stratify&#xD;
      patients for two different radiotherapy regimens based on the presence/absence of&#xD;
      identifiable intraprostatic lesions.&#xD;
&#xD;
      In patients without identifiable prostate cancer lesions, SBRT to the prostate in 5 sessions&#xD;
      (fractions) will be administered.&#xD;
&#xD;
      In patients with MRI-identified lesion(s), pelvic IMRT in 25 fractions will be administered&#xD;
      followed by an SBRT prostate boost while simultaneously treating the prostate cancer&#xD;
      lesion(s) to a higher dose in 3 fractions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiotherapy (RT) is considered standard of care treatment for prostate cancer. Conventional&#xD;
      RT regimens consist of 8-9 weeks of daily RT. Recent data support the use of hypofractionated&#xD;
      RT (5-6 weeks) due to similar disease control in a contracted treatment time. This study&#xD;
      combines the benefits of RT dose escalation while shortening the overall RT treatment course.&#xD;
&#xD;
      In this protocol, patients will undergo a pretreatment mpMRI prostate scan and be stratified&#xD;
      to two separate SBRT regimens depending on whether prostate lesions are present. For patients&#xD;
      without any positive mpMRI lesions, an SBRT monotherapy (36.25 Gy in 5 fractions) approach&#xD;
      will be utilized. Patients with an equivocal or positive mpMRI lesion(s), will receive&#xD;
      IG-IMRT (45 Gy in 25 fractions) to prostate and seminal vesicle +/- lymph nodes followed by a&#xD;
      SBRT whole prostate boost (18 Gy in 3 fractions) with a simultaneously integrated boost (SIB)&#xD;
      (21 Gy in 3 fractions) to intraprostatic lesion(s) only.&#xD;
&#xD;
      Patients will be regularly assessed every 3 months for the first 2 years and then every 6&#xD;
      months, indefinitely. Side effects will be monitored using the standardized international&#xD;
      prostate symptom score (I-PSS) and Sexual Health Inventory of Men (SHIM) questionnaires at&#xD;
      baseline and subsequent follow-up appointments.&#xD;
&#xD;
      Hypothesis: MRI-guided treatment planning and delivery can selectively target high-risk&#xD;
      prostate cancer nodules and deliver a higher effective RT dose, to achieve maximal tumor&#xD;
      control without increasing toxicity, all in a shortened treatment duration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 23, 2016</start_date>
  <completion_date type="Anticipated">March 2029</completion_date>
  <primary_completion_date type="Actual">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Late Radiation Induced Genitourinary and Gastrointestinal Toxicity</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Acute Radiation Induced Genitourinary Toxicity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Recurrence</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free-Survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Negative mpMRI Prostate Scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT to the whole prostate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive mpMRI Prostate Scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMRT to the prostate + seminal vesicles followed by SBRT boost to the whole prostate with SIB to MRI defined intraprostatic lesions</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT to whole prostate</intervention_name>
    <description>Those patients with negative mpMRI prostate scan (PI-RADS 0-2) will receive SBRT (36.25 Gy/5 fractions) to the whole prostate</description>
    <arm_group_label>Negative mpMRI Prostate Scan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT followed by mpMRI guided SBRT boost with SIB to intraprostatic lesions</intervention_name>
    <description>Patients with positive or equivocal mpMRI prostate scan (PI-RADS 3-5) will receive IMRT (45 Gy/25 fractions) to the prostate + seminal vesicles +/- lymph nodes followed by SBRT boost (18 Gy/3 fractions) to the whole prostate with simultaneous integrated boost (21 Gy/3 fractions) to MRI defined intraprostatic lesions</description>
    <arm_group_label>Positive mpMRI Prostate Scan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy proven prostate adenocarcinoma within 1 year of randomization&#xD;
&#xD;
          -  NCCN Low to High Risk localized prostate cancer&#xD;
&#xD;
          -  Zubrod Performance Status 0-1 within 60 days prior to registration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior or concurrent invasive malignancy (except non-melanoma skin cancer)&#xD;
&#xD;
          -  Regional Lymph Node (N1) involvement&#xD;
&#xD;
          -  Distant Metastases (M1) involvement&#xD;
&#xD;
          -  History of prior pelvic irradiation (external beam radiotherapy or brachytherapy)&#xD;
&#xD;
          -  Prior chemotherapy&#xD;
&#xD;
          -  Severe, active co-morbidities (unstable angina and/or CHF; MI; COPD; liver disease;&#xD;
             AIDS)&#xD;
&#xD;
          -  Acute bacterial or fungal infection requiring IV antibiotics&#xD;
&#xD;
          -  Inability to undergo MRI&#xD;
&#xD;
          -  Inability to receive fiducial markers&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dian Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 14, 2018</study_first_submitted>
  <study_first_submitted_qc>December 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>January 24, 2021</last_update_submitted>
  <last_update_submitted_qc>January 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>Dian Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>SBRT</keyword>
  <keyword>Stereotactic Body Radiotherapy</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 21, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT03778112/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

